PLF Pharma, a pioneering leader in the UK medical cannabis industry, is thrilled to announce a significant advancement in its mission to provide quality healthcare solutions. Following rigorous inspections by the UK Regulators we are excited to share that we have been granted a Wholesale Distribution Authorisation (WDA) and a Manufacturers Specials (MS) licence.
This milestone will improve medical cannabis distribution and enables accessibility in the United Kingdom. PLF Pharma is now able to import a diverse range of medical cannabis products from renowned global sources enabling efficient distribution to patients who hold prescriptions for their specific medical conditions.
Through strategic partnerships, PLF have access to the finest medical cannabis products that meet with the stringent UK pharmaceutical requirements.
“We are delighted to share this news with our investors, partners, and the larger healthcare industry,” said Karl Spratt, CEO of PLF Pharma. “These licences signify a new chapter in our journey to provide accessible and effective medical solutions. We remain dedicated to our mission of improving lives and will continue to uphold the highest standards of quality and service.”
About PLF Pharma:
PLF Pharma (Hempire Limited) has pioneered the UK medical cannabis industry since 2014.
The company has a UK facility operating since 2015. This presents an opportunity to investors who would like to be part of a company with the aim of helping the 8 million people who suffer from chronic pain in the UK.
Construction of the premises is complete and a new funding round of £1.6m is about to start. This round will equip and validate the facility to comply with EU-GMP enabling the sale of UK cultivated cannabis medicines.
For further inquiries, please contact:
Paul@plfpharma.co.uk +44 7956 096751 or Karl@plfpharma.co.uk +44 7989 403272
